| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ECL; SLC; CKb9; TCA4; 6Ckine; SCYA21;;CCL21 |
| WB Predicted band size | 15 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human CCL21 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于CCL21抗体的3篇参考文献示例(文献信息为虚构，仅供格式参考)：
---
1. **文献名称**：*Targeting CCL21 with a monoclonal antibody inhibits lymph node metastasis in breast cancer*
**作者**：Smith A, et al.
**摘要**：该研究开发了一种抗CCL21的单克隆抗体，通过阻断CCL21与其受体CCR7的相互作用，显著抑制乳腺癌小鼠模型中的淋巴结转移，表明其潜在治疗价值。
2. **文献名称**：*CCL21-neutralizing antibody attenuates autoimmune inflammation in rheumatoid arthritis*
**作者**：Li Y, et al.
**摘要**：研究发现，使用CCL21中和抗体可减少类风湿性关节炎模型中的炎性细胞浸润和关节破坏，揭示了CCL21在自身免疫中的调控作用及抗体治疗的可行性。
3. **文献名称**：*A novel anti-CCL21 antibody enhances T cell infiltration in tumor microenvironment*
**作者**：Wang X, et al.
**摘要**：该文献报道了一种新型抗CCL21抗体，通过调节肿瘤微环境中的趋化因子梯度，促进细胞毒性T细胞向肿瘤部位聚集，增强免疫检查点抑制剂的疗效。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“CCL21 antibody”筛选近期研究。
CCL21 (C-C motif chemokine ligand 21) is a small signaling protein belonging to the chemokine family, primarily involved in immune cell trafficking and lymphoid tissue organization. It binds to the CCR7 receptor, guiding dendritic cells, T cells, and B cells to specific sites during immune responses. CCL21 exists in two isoforms: CCL21a (SCYA21) and CCL21b (6Ckine), with distinct expression patterns. CCL21a is constitutively expressed in lymphatic endothelial cells and stromal cells, while CCL21b is induced during inflammation.
Antibodies targeting CCL21 are critical tools for studying its role in diseases. In cancer, CCL21 facilitates lymphocyte infiltration and tumor microenvironment modulation but may also promote metastasis by directing CCR7+ cancer cells to lymph nodes. In autoimmune disorders, dysregulated CCL21 expression contributes to chronic inflammation. Anti-CCL21 antibodies enable researchers to block this chemokine-receptor interaction, dissecting its mechanistic contributions or exploring therapeutic potential.
Commercial CCL21 antibodies are typically developed in hosts like rabbits or mice, validated for applications such as ELISA, immunohistochemistry, or flow cytometry. Some studies also use neutralizing antibodies to inhibit CCL21 signaling in preclinical models. Challenges include ensuring specificity due to homology with other chemokines. Current research focuses on leveraging anti-CCL21 strategies to modulate immune responses in immunotherapy or disrupt pathological cell migration in inflammatory diseases.
×
